Literature DB >> 10961902

Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K.

M T Moran1, J P Schofield, A R Hayman, G P Shi, E Young, T M Cox.   

Abstract

Deficiency of lysosomal acid beta-glucosidase induces glycolipid storage in the macrophages of Gaucher disease but the pathways of multisystem tissue injury and destruction are unknown. To investigate the cognate molecular pathology of this inflammatory disorder, genes that were differentially expressed in spleen samples from a patient with Gaucher disease (Gaucher spleen) were isolated. Of 64 complementary DNA (cDNA) fragments sequenced from an enriched Gaucher cDNA library, 5 encode lysosomal proteins (cathepsins B, K, and S, alpha-fucosidase, and acid lipase), 10 encode other known proteins, and 2 represent novel sequences from human macrophage cell lines. Transcript abundance of the cathepsins, novel genes, pulmonary and activation-regulated chemokine (PARC), and NMB, a putative tumor suppressor gene, was greatly increased. Immunoblotting showed increased mature forms of all 3 cathepsins found in samples of Gaucher spleens. Immunofluorescence microscopy showed strong cathepsin B and K reactions in sinusoidal endothelium and Gaucher cells. The respective means, plus or minus SD, of cathepsin B, K, and S activities were 183 +/- 35, 97 +/- 39, and 91 +/- 45 nmol/min/mg protein in 4 Gaucher spleens, and 26 +/- 4, 10.5 +/- 2, and 4.0 +/- 2.1 nmol/min/mg protein in 3 control spleens. Plasma cathepsin B, K, and S activities were also elevated in Gaucher disease plasma (P <.001), but compared with control plasma samples, neither cathepsin B nor K activities were significantly elevated in 8 patients with nonglycosphingolipid lysosomal storage diseases or in 9 patients with other glycosphingolipidoses, which suggests disease specificity. All 3 cathepsin activities were increased 2-fold to 3-fold in Gaucher sera compared with control sera. In all 6 patients treated by enzyme replacement for 16-22 months, serum cathepsin activities decreased significantly (P <.01). Longitudinal studies confirmed the progressive reduction of proteinase activities during imiglucerase therapy but in 3 Gaucher patients with mild disease not so treated, serum cathepsin activities remained constant or increased during follow-up. Enhanced expression of cysteine proteinases may promote tissue destruction. Moreover, the first identification of aberrant cathepsin K expression in hematopoietic tissue other than osteoclasts implicates this protease in the breakdown of the matrix that characterizes lytic bone lesions in Gaucher disease. (Blood. 2000;96:1969-1978)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10961902

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

Review 1.  Are there useful biochemical markers of disease activity in lysosomal storage diseases?

Authors:  B Winchester
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

Review 2.  Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.

Authors:  F M Platt; M Jeyakumar; U Andersson; D A Priestman; R A Dwek; T D Butters; T M Cox; R H Lachmann; C Hollak; J M Aerts; S Van Weely; M Hrebícek; C Moyses; I Gow; D Elstein; A Zimran
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

3.  Bilateral symmetrical cortical osteolytic lesions in two patients with Gaucher disease.

Authors:  Ian M Oppenheim; Astrid Medina Canon; William Barcenas; Catherine Groden; Ozlem Goker-Alpan; Charles S Resnik; Ellen Sidransky
Journal:  Skeletal Radiol       Date:  2011-09-20       Impact factor: 2.199

4.  Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome.

Authors:  Philippe M Campeau; Moutih Rafei; Marie-Noëlle Boivin; Ying Sun; Gregory A Grabowski; Jacques Galipeau
Journal:  Blood       Date:  2009-07-08       Impact factor: 22.113

5.  Aberrant progranulin, YKL-40, cathepsin D and cathepsin S in Gaucher disease.

Authors:  Yuliya Afinogenova; Jiapeng Ruan; Ruhua Yang; Nathaniel Kleytman; Gregory Pastores; Andrew Lischuk; Pramod K Mistry
Journal:  Mol Genet Metab       Date:  2019-07-23       Impact factor: 4.797

6.  CCL18: a urinary marker of Gaucher cell burden in Gaucher patients.

Authors:  Rolf G Boot; Marri Verhoek; Mirjam Langeveld; G Herma Renkema; Carla E M Hollak; Jan J Weening; Wilma E Donker-Koopman; Johanna E Groener; Johannes M F G Aerts
Journal:  J Inherit Metab Dis       Date:  2006-05-30       Impact factor: 4.982

7.  Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease.

Authors:  Vagishwari Murugesan; Jun Liu; Ruhua Yang; Haiquin Lin; Andrew Lischuk; Gregory Pastores; Xiaokui Zhang; Wei-Lien Chuang; Pramod K Mistry
Journal:  Blood Cells Mol Dis       Date:  2016-12-13       Impact factor: 3.039

Review 8.  An overview on bone manifestations in Gaucher disease.

Authors:  Peter Mikosch; Derralynn Hughes
Journal:  Wien Med Wochenschr       Date:  2010-12

9.  Probing cathepsin K activity with a selective substrate spanning its active site.

Authors:  Fabien Lecaille; Enrico Weidauer; Maria A Juliano; Dieter Brömme; Gilles Lalmanach
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

10.  Cathepsin K: a cysteine protease with unique kinin-degrading properties.

Authors:  Emmanuel Godat; Fabien Lecaille; Claire Desmazes; Sophie Duchêne; Enrico Weidauer; Paul Saftig; Dieter Brömme; Christophe Vandier; Gilles Lalmanach
Journal:  Biochem J       Date:  2004-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.